Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sunday newspaper round-up: Restrictions, Unemployment, Blood plasma

Sun, 29th Mar 2020 20:57

(Sharecast News) - "Life in Britain will not return to normal for six months, England's deputy chief medical officer has warned, as ministers begin preparing the public for an extended period of lockdown. At the government's daily press conference, Jenny Harries said that strict social distancing rules may have to be in place for between two and three months. But she added that it would be a further three months before all restrictions were lifted, and even then there were likely to be "bumps" as new clusters of cases of coronavirus were identified." - Sunday Times
Unemployment in Britain is set to more than double in coming months, despite government efforts to incentivise employers to keep staff. Economists warn that the rise in the second quarter of the year will be even sharper than during the financial crisis in 2008. Nomura, the investment bank, predicts an unemployment rate of 8% in the April-June quarter, rising to 8.5% in the following three months, from 3.9% in January, as GDP falls sharply. The 8% rate would be the equivalent of an additional 1.4 million people unemployed and a total jobless level of 2.75 million. - Sunday Times

Rolls-Royce is facing a cash flow crisis as the collapse in air travel caused by coronavirus sees half of its revenues evaporate, leaving the FTSE 100 engineer scrambling for cash. Within days of the scale of the crisis becoming clear, Rolls drew down ?2.5bn of funding to boost its liquidity to ?7bn. However, with the company depending on its civil aerospace business for half of its ?15.4bn underlying revenue, it is likely to need further funding as the coronavirus crisis drags on. - Sunday Telegraph

Doctors have drawn up plans to infuse British coronavirus patients and their carers with blood plasma harvested from "hyperimmune" people who have recovered from the infection in an attempt to save lives. The experimental treatment will be directed at patients who are admitted to hospital with pneumonia caused by the virus in the hope that it reduces the number who end up on ventilators in intensive care units (ICUs). - Guardian

"Italy's political leaders from Left to Right have erupted in fury over the EU's minimalist, insulting, and cack-handed response to the Covid-19 pandemic, warning that lack of economic solidarity risks pushing the bloc's festering divisions beyond the point of no return. "Don't make a tragic mistake. The whole European edifice risks losing its raison d'etre," said the Italian premier, Giuseppe Conte, demanding a giant Marshall Plan funded on the EU's joint credit card to relaunch the productive system once the current nightmare is over." - Sunday Telegraph

Scores of Britain's best-known high street food and drink chains will go bust by the end of April unless banks provide immediate finance, the head of the hospitality industry has warned. Kate Nicholls, chief executive of the UK Hospitality trade body, said further failures are 'inevitable' after 80- strong restaurant chain Chiquitos - owned by The Restaurant Group, whose chief executive is ex-HBOS bank boss Andy Hornby - and the 73-outlet Carluccio's lined up administrators. Nicholls said short-term loans from banks are vital to cover costs pending the arrival of Government grant packages. - UK Daily Mail

Synairgen, listed on the London Stock Exchange and worth just ?50m, is starting a clinical trial in hospitals across the UK with a drug it hopes will prevent coronavirus sufferers from falling seriously ill. [...] Synairgen will now test the treatment on 100 patients with coronavirus. Half will be given its new drug, half will get a placebo. Results could arrive in as soon as eight weeks, which could pave the way for a fast-tracked pivotal study in a bigger group of patients and rapid approval. - Sunday Times

More News
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
26 May 2020 13:55

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Synairgen Loss Widens; Progressing On SNG001 Study For Covid-19

Read more
31 Mar 2020 12:21

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Read more
29 Mar 2020 21:00

Sunday share tips: Synairgen, Hollywood Bowl

(Sharecast News) - The Sunday Times's Sabah Meddings recommends buying shares of Synairgen arguing that the Covid-19 pandemic may have given the firm a new lease on life.

Read more
26 Mar 2020 14:26

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

UPDATE: Synairgen Successfully Raises Cash For Covid-19 Trials

Read more
26 Mar 2020 06:58

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Synairgen Raises Cash To Go Towards Covid-19 Drug Trial

Read more
18 Mar 2020 18:42

Britain's Synairgen gets green light for coronavirus drug trial

By Paul SandleLONDON, March 18 (Reuters) - British pharmaceutical company Synairgen said on Wednesday it had the go-ahead to test a drug that could boost the lung function of patients with coronavirus, potentially assisting in the global fight aga...

Read more
18 Mar 2020 16:59

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Synairgen Gets Expedited UK Approval To Trial SNG001 For Covid-19

Read more
18 Mar 2020 11:17

Synairgen to begin trial of potential Covid-19 therapy

(Sharecast News) - Respiratory drug discovery company Synairgen has received expedited approvals from the Medicines and Healthcare Products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of 'SNG001', an inhaled formulation of interferon-beta-1a, in Covid-19 coronavirus patients, to potentially assist with the global virus pandemic.

Read more
1 Oct 2019 13:42

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Synairgen Interim Loss Deepens On Costs As Progresses Clinical Trials

Read more
27 Sep 2019 13:32

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Synairgen Expects Positive Outcome From Second Part Of SNG001 Study

Read more
24 Jul 2019 12:58

Synairgen Encouraged By Findings So Far In Interferon Beta COPD Study

(Alliance News) - Synairgen PLC on Wednesday said a phase two trial in its inhaled interferon beta programme has found cold and flu infections worsen symptoms for chronic obstructive pulmonary in

Read more
9 Jul 2019 09:26

CORRECT (Jul 8): Woodford Transfers Company Stakes After Omnis Departs

(Correcting that Woodford Investment Management transferred a number of stakes following Omnis's decision. It did not sell these stakes, as was originally reported.)(Alliance News) - of

Read more
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.